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While there is no reliable serum biomarker for the diagnosis and monitoring of patients with gastric cancer, we tested the potential
diagnostic and prognostic values of detecting methylation changes in the serum of gastric cancer patients. DNA was extracted from
the pretherapeutic serum of 60 patients with confirmed gastric adenocarcinoma and 22 age-matched noncancer controls. Promoter
hypermethylation in 10 tumour-related genes (APC, E-cadherin, GSTP1, hMLH1, MGMT, p15, p16, SOCS1, TIMP3 and TGF-beta RII) was
determined by quantitative methylation-specific PCR (MethyLight). Preferential methylation in the serum DNA of gastric cancer
patients was noted in APC (17%), E-cadherin (13%), hMLH1 (41%) and TIMP3 (17%) genes. Moreover, patients with stages III/IV
diseases tended to have higher concentrations of methylated APC (P¼0.08), TIMP3 (P¼0.005) and hMLH1 (P¼0.03) in the serum.
In all, 33 cancers (55%) had methylation detected in the serum in at least one of these four markers, while three normal subjects had
methylation detected in the serum (specificity 86%). The combined use of APC and E-cadherin methylation markers identified a
subgroup of cancer patients with worse prognosis (median survival 3.3 vs 16.1 months, P¼0.006). These results suggest that the
detection of DNA methylation in the serum may carry both diagnostic and therapeutic values in gastric cancer patients.
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Gastric cancer is the second most common cause of cancer-related
mortality in the world that killed more than 640000 patients each
year (Globocan, 2000). Although screening for gastric cancer may
improve the overall survival of cancer patients by identifying early
cancers, a reliable simple and noninvasive screening test is lacking.
In particular, there is no serum biomarker for gastric cancer. The
recent rapid advancement in molecular or biochemical techniques
may help to identify novel serum markers to be used for this
purpose. Apart from screening, these serum biomarkers may also
help to stratify cancer patients according to the risk of recurrence.
Epigenetic silencing of tumour-associated genes by promoter
hypermethylation is increasingly recognised to play an instru-
mental role in cancer development (Egger et al, 2004). These
changes, which involve DNA and histone modifications, result in
the heritable silencing of genes without a change in their coding
sequence. We and others have previously demonstrated the
frequent hypermethylation of CpG islands within the promoter
regions of genes like hMLH1, E-cadherin, p15, p16, and APC in
gastric cancer (Tsuchiya et al, 2000; Leung et al, 2001; To et al,
2002; Kang et al, 2003; Sarbia et al, 2004). Moreover, these
epigenetic alterations could be readily detected in the tumour-
derived DNA recovered from the serum of gastric cancer patients
(Lee et al, 2002). With the growing number of methylation markers
and the development of high-throughput techniques, we deter-
mined the potential diagnostic and prognostic significance of
detecting gene methylation in the serum DNA of patients with
adenocarcinoma of stomach by the use of a quantitative DNA
methylation assay, MethyLight.
MATERIALS AND METHODS
Patients and control
A total of 60 Chinese patients with confirmed gastric adenocarci-
noma were examined (male 58.3%, mean age¼66 years, range 35–
96 years). The majority (78%) of cancers were located in the distal
stomach. None of these patients had family history of gastric
cancer. In all, 22 age- and gender-matched subjects with normal
upper gastroscopy were included as control. All blood samples
were collected at the time of diagnosis, usually at the time of
endoscopy, prior to any therapeutic intervention. Baseline
demographic data of patients were recorded. Tumour was staged
according to the sixth edition of the TNM staging system (Sobin
and Wittekind, 2002). Staging information was available in 54
patients. There were five stage I, seven stage II, 13 stage III and 29
stage IV cancers. All cancer patients were treated according to a
standard protocol with surgery being the mainstay of treatment.
Patients were being regularly followed up in our clinic and the
median follow-up duration since the time of diagnosis was 8
months (range 0– to 40 months). In total, 34 (56.7%) patients died
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sin the follow-up period. Two patients died in the early post-
operative period were excluded in the subsequent survival analysis.
All patients and controls gave informed consent for participa-
tion in this study and the study protocol was approved by the
Clinical Research Ethics Committee of the Chinese University of
Hong Kong.
DNA extraction and modification
Serum samples obtained from cancer patients and controls were
randomly coded before processing to ensure adequate blinding of
the clinical information. The serum was separated by centrifuga-
tion and stored at  201C prior to processing. Genomic DNA was
extracted from 800ml serum with commercially available DNA
extraction kit (QIAamp Blood Kit; Qiagen Hilden, Germany). The
DNA was then chemically modified by sodium bisulphite to
convert all unmethylated cytosines to uracils while leaving
methylcytosines unaltered (EZ DNA methylation kit; Zymo
Research, Orange, CA, USA), and eluted in 50ml of elution buffer.
Methylation-specific PCR (MSP)
The fluorescence-based real-time PCR assay, MethyLight, was used
in the detection of methylated DNA in the serum (Eads et al, 2000,
2001). A total of 10 tumour-related genes were examined: APC,
E-cadherin, GSTP1, hMLH1, MGMT, p15, p16, SOCS1, TIMP3
and TGF-beta RII. These genes were previously reported to be
methylated in various human cancers (Eads et al, 2001; To et al,
2004). The sequences of the primers and fluorogenic probes were
listed in Table 1.
For each amplification, 5ml of bisulphite converted DNA,
equivalent to DNA extracted from 80ml of the serum, was used.
PCR was performed in a 25ml reaction volume consisting of 5pmol
of each primer, 250pmol of probe, 200mM each of dATP, dCTP and
dGTP, 400mM dUTP, 3.5mM MgCl2,1 TaqMan Buffer A and 2U
of AmpliTaq Gold polymerase at the following condition: 951C for
10min, followed by 50 cycles at 951C for 15s and 601C for 1min.
All PCR was performed in iCycler iQ Real-Time PCR Detection
system (BioRad, Hercules, CA, USA). CpGenomet Universal
methylated DNA (Chemicon International Inc., CA, USA) was
included in all amplifications as positive control and internal
reference, whereas bisulphite-modified human sperm DNA was
used as negative control. A standard curve was created by plotting
the logarithmic of the amount of standard universal methylated
DNA in the range of 31.25pg–10ng against the threshold cycle
value. The minimal correlation coefficient for each quantitative
MSP was 0.98. The corresponding amount of methylated DNA in
the serum samples was calculated from the standard curve. A
serum DNA sample was considered to be methylated when the
level of methylated DNA was greater than or equivalent to 0.05ng
in 80ml serum. This level was determined after adjustment to the
background level detected in normal subjects (data not shown).
A methylation marker was considered to be preferentially
methylated in gastric cancer patients when the following criteria
were met (Muller et al, 2003): (1) unmethylated in serum samples
of healthy control but methylated in more than 10% of serum
samples from gastric cancer patients or (2) p10% methylated in
serum samples of normal control but methylated in 420% of
serum samples of gastric cancer patients.
Statistical analysis
Statistical analysis was performed by using SPSS software (version
11.5; SPPS, Chicago, IL, USA). Categorical data were analysed by
Fisher’s exact test, whereas numerical value was compared by
Student’s t-test. One-way ANOVA was used in the comparison of
the concentrations of methylated DNA among control subjects,
and patients with early (stages I and II) and advanced (stages III
and IV) cancer. The Kaplan–Meier method was used for univariate
survival analysis and the log-rank test was used to compare the
difference in survival curves. The presence of methylated DNA in
the serum was analysed in a dichotomous manner (i.e. methylated
or unmethylated) during survival analysis. Those who died from
postoperative complications were excluded for survival analysis. A
P-value of less than 0.05 was considered to be statistically
significant.
RESULTS
DNA methylation in the serum
The frequency of DNA methylation in the serum of gastric cancer
patients and controls was shown in Figure 1. By using the
predefined criteria (Muller et al, 2003), differential methylation
Table 1 Summary of primer sequences and probe used for quantitative MSP
Marker Primer sequences Probe Ref.
APC GAACCAAAACGCTCCCCAT (forward)
TTATATGTCGGTTACGTGCGTTTATAT (reverse)
6FAM-CCCGTCGAAAACCCGCCGATTA-TAMRA Eads et al, 2001
E-cadherin AATTTTAGGTTAGAGGGTTATCGCGT (forward)
TCCCCAAAACGAAACTAACGAC (reverse)
6FAM-CGCCCACCCGACCTCGCAT-TAMRA Eads et al, 2001
GSTP1 GTCGGCGTCGTGATTTAGTATTG (forward)
AAACTACGACGACGAAACTCCAA (reverse)
6FAM-AAACCTCGCGACCTCCGAACCTTATAAAA-TAMRA Eads et al, 2001
hMLH1 CGTTATATATCGTTCGTAGTATTCGTGTTT (forward)
CTATCGCCGCCTCATCGT (reverse)
6FAM-CGCGACGTCAAACGCCACTACG-TAMRA Eads et al, 2001
p15 AGGAAGGAGAGAGTGCGTCG (forward)
CGAATAATCCACCGTTAACCG (reverse)
6FAM-TTAACGACACTCTTCCCTTCTTTCCCACG-TAMRA Eads et al, 2001
p16 TGGAATTTTCGGTTGATTGGTT (forward)
ACAACGTCCGCACCTCCT (reverse)
6FAM-ACCCGACCCCGAACCGCG-TAMRA Eads et al, 2001
TIMP3 GCGTCGGAGGTTAAGGTTGTT (forward)
CTCTCCAAAATTACCGTACGCG (reverse)
6FAM-AACTCGCTCGCCCGCGAA-TAMRA Eads et al, 2001
MGMT CTAACGTATAACGAAAATCGTACAACC (forward)
AGTATGAAGGGTAGGAAGAATTCGG (reverse)
6FAM-CCTTACCTCTAAATACCAACCCCAAACCCG-TAMRA Eads et al, 2001
TGF-beta RII GCGCGGAGCGTAGTTAGG (forward)
CAAACCCCGCTACTCGTCAT (reverse)
6FAM-CACGAACGACGCCTTCCCGAA-TAMRA Eads et al, 2001
SOSC1 ACGTCGATTATCGGCGTATTAC (forward)
CGCTCAAAAACCCCCAAT (reverse)
6FAM-TTTGGACGTTTGCGGATTT-TAMRA To et al, 2004
MSP¼methylation-specific PCR.
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swas detected in APC, E-cadherin, hMLH1 and TIMP3. The
frequency of detecting methylated DNA in the serum of cancer
patients for APC was 17%, E-cadherin was 13%, hMLH1 was 41%
and TIMP3 was 17%. On the other hand, differential methylation
pattern was not observed in the remaining tumour-related genes
due to either lack of specificity (p15, p16, SOCS1 and MGMT) or
low methylation frequency (TGF-beta RII and GSTP1).
To further test the specificity of detecting methylated DNA in
serum, we determined the methylation status of APC, E-cadherin,
hMLH1 and TIMP3 in primary gastric cancer tissues by MSP.
Among the 33 gastric cancers with DNA available for analysis, the
corresponding number of cases with promoter hypermethylation
in primary cancer tissues for APC, E-cadherin, hMLH1 and TIMP3
was 20 (61%), five (15%), 14 (42%) and five (15%). It was apparent
from this paired comparison that nearly all tumours with
methylation in E-cadherin, hMLH1 and TIMP3 had methylation
detected in the serum DNA as well. Moreover, all patients with
methylation detected in the serum DNA had methylation in the
corresponding tumours.
With the combined use of the four methylation markers that
exhibited differential methylation in cancer (APC, E-cadherin,
hMLH1 and TIMP3), 33 (55%) patients had methylated serum
DNA detected in at least one of these markers. In contrast, three
normal subjects had methylated DNA detected in the serum, and
hence, the specificity of this panel of markers was 86%. With the
use of this panel of markers, the median number of genes
methylated in the serum of cancer patients and control was 1 and
0, respectively (Figure 2).
Clinicopathological correlation
High level of methylated DNA was more frequently detected in
the serum of patients with more advanced cancer (Figure 3).
Specifically, patients with stages III/IV diseases tended to have
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Figure 1 Frequency of detecting methylated DNA in the serum of
gastric cancer patients and control. *Genes with differential methylation in
cancer patients according to predefined criteria.
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Figure 2 Number of genes methylated in the serum of gastric cancer
patients and control.
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Figure 3 Association between cancer staging and concentrations of methylated DNA. (A) APC (P¼0.08); (B) E-cadherin (P¼0.2); (C) TIMP3
(P¼0.005) and (D) hMLH1 (P¼0.03). The horizontal line indicated the median concentrations of the patients’ subgroups.
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shigher concentrations of methylated APC (P¼0.08), TIMP3
(P¼0.005) and hMLH1 in the serum (P¼0.03). On the other
hand, there was no significant association between the levels of
methylated E-cadherin DNA and tumour staging (P¼0.2).
The potential association between methylated DNA in serum
and patients’ demographic data was investigated. Notably, patients
with methylated hMLH1 in the serum were slightly younger than
patients with unmethylated hMLH1 (61.2 vs 69.3 years, P¼0.045).
There was no other association between the presence of methylated
DNA in the serum and patients’ characteristics.
DNA methylation and survival
Apart from determining its diagnostic accuracy, we examined the
potential prognostic value of detecting DNA methylation in the
pretherapeutic serum of gastric cancer patients. Patients with
methylated APC DNA in serum tended to have a nonsignificant
shorter survival than patients with unmethylated APC. The
difference appeared to be more marked in the initial 18 months
of diagnosis. The overall median survival of patients with and
without methylated APC in serum was 5.5 and 16.1 months,
respectively (P¼0.20, Figure 4A). Conversely, those with methy-
lated E-cadherin tended to have a longer survival than patients
with unmethylated gene (median survival 32.1 vs 14.1 months,
P¼0.09, Figure 4B). The presence of methylated hMLH1 and
TIMP3 DNA in the serum was not associated with overall patients’
survival (P¼0.40 and 0.58, respectively).
When combining the two methylation markers APC and E-
cadherin, patients with methylated APC and unmethylated E-
cadherin in the serum were found to have a significantly worse
prognosis when compared to those without these alterations
(median survival 3.3 vs 16.1 months, P¼0.006, Figure 4). Other
combinations of methylation markers were not found to have any
correlations with patients’ survival.
DISCUSSION
Unlike many other cancers, a reliable serum biomarker for gastric
cancer is lacking. In particular, a serum marker that may carry
both diagnostic and prognostic implication is currently unavail-
able. In this study, we characterised the significance of detecting
DNA methylation in the serum of gastric cancer patients. Of the 10
methylation markers examined, differential methylation was noted
in the following genes: APC, E-cadherin, hMLH1 and TIMP3.B y
using this panel of methylation markers, 55% of gastric cancer had
methylated DNA detected in the serum. This is higher than the
previous report by Koike et al (2004) in which 44% of patients
were found to have methylation in p16, E-cadherin and/or RARb.
Furthermore, we determined the concentration of methylated
DNA in the serum of cancer patients and controls by using the
quantitative MSP assay. We found that the concentrations of
methylated APC, hMLH1 and TIMP3 were higher in patients with
advanced stage cancer. Similar stage-dependent increase in
methylated APC DNA was also noted in patients with oesophageal
adenocarcinoma (Kawakami et al, 2000), which may be related to
the heavy tumour load in patients with more advanced cancer.
Although Nakajima et al (2001) showed that frequency of hMLH1
methylation in gastric cancer significantly increase with ages, we
found that the detection of methylated hMLH1 in the serum was
slightly more common in younger patients. Further studies may be
needed to characterise the sources and mechanisms of tumour
DNA circulating in blood to give a better explanation for this
observation.
In this study, we found that the presence of methylated APC
or unmethylated E-cadherin in the pretherapeutic serum of cancer
patients tended to have a nonsignificant trend towards poor
survival. In particular, the presence of methylated APC and
unmethylated E-cadherin in the serum had a lower survival chance
than those without these alterations. Recently, several studies have
demonstrated the potential prognostic significance of detecting
aberrant promoter hypermethylation in the serum/plasma of
patients with oesophageal (Kawakami et al, 2000), lung (Usadel
et al, 2002) and breast (Muller et al, 2003) cancers. Kawakami et al
(2000) reported that the presence of high plasma levels of
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Figure 4 Kaplan–Meier analysis of the probability of overall survival in
gastric cancer patients according to methylation status. (A) APC (P¼0.20);
(B) E-cadherin (P¼0.09); (C) combined APC and E-cadherin (P¼0.006).
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smethylated APC DNA were associated with reduced survival in
patients with oesophageal adenocarcinoma. In addition, Muller
et al (2003) demonstrated that the presence of methylated APC
and/or RASSF1A was associated with poor outcome in patients
with breast cancer. Interestingly, our data showed that patients
with methylated E-cadherin in serum tended to have a higher
survival chance. Past studies found that E-cadherin methylation
may be more common in the undifferentiated diffuse-type gastric
cancer (Tamura et al, 2000). On the other hand, there was no
reported association between the presence of E-cadherin methyla-
tion in the serum and survival of cancer patients. It remains elusive
whether the difference in survival is related to the preferential
methylation in E-cadherin in different histological subtypes of
cancer. Owing to the relatively small sample size and the low
frequency of E-cadherin in the serum, we were unable to perform
subgroup analysis according to histological subtypes. Studies with
larger sample size may be necessary to discern the potential
prognostic significance of detecting E-cadherin methylation in
the serum of gastric cancer patients with different histological
subtypes.
Based on the differential methylation patterns of different
methylation markers, it is obvious that the sensitivity and
specificity of these methylation markers may vary in different
tumour types. As shown by previous studies (Eads et al, 2001;
Muller et al, 2003), some of these methylation markers are detected
in very high frequency even in the serum of normal individuals,
whereas some markers are never methylated in the serum of cancer
patients. By using the predefined criteria, we have determined the
panel of markers that are specific for gastric cancer. The detection
rates of this study were different from our previous report (Lee
et al, 2002), which may be accounted by the changes in
methylation detection methods. In particular, methylated E-
cadherin was detected in the serum of more than 50% of cancer
patients by using conventional MSP in our previous study. By
using quantitative MethyLight assay, a lower detection rare of 13%
was obtained. Apart from the difference in PCR primers, the
MethyLight includes an internal fluorogenic probe, which in-
creases the specificity of the assay.
The major advantage in detecting aberrantly methylated DNA
in the serum is the convenience and simplicity of the test. With
the use of high-throughput fluorescence-based real-time PCR
(MethyLight), multiple tumour-related genes or multiple patients’
samples can be processed at the same time. For instance, a typical
single PCR reaction takes less than 2h and could provide
invaluable information on screening as well as on prognosis. With
the identification of more and more methylation markers, it is
anticipated that the positive rates, or sensitivity, of detecting
methylated DNA in the serum of gastric cancer patients will rise.
It will also be interesting to determine in future studies whether
aberrantly methylated serum DNA would be useful in monitoring
of disease progression or treatment response in patients with
gastric cancer.
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